National Institute for Health and Care Research (NIHR)
Meet NIHR at the UK Pavilion, booth 38.
NIHR is committed to funding health, public health and social care research that leads to improved outcomes for patients and the public, and makes the health and social care system more efficient , effective and safe. We work closely with stakeholders across the system to ensure we address the challenges they face and are responsive to their research needs.
Karl Davison
Business Development ManagerAmy Yarker
Business Development ManagerAlicia Cox
Senior Business Development ManagerHarvey Badwal
Senior Business Development Manager
TheraCryf
Meet TheraCryf at the UK Pavilion, booth 38.
TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma.
Formerly Evgen Pharma plc, the Company acquired Chronos Therapeutics in April 2024. TheraCryf, the new name for the Group, reflects a wider mission and broader portfolio. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.
Dr Helen Kuhlman
Chief Business OfficerDr Huw Jones
Chief Executive Officer
ViaNautis Bio
ViaNautis is exploiting its proprietary technology, polyNaut®, a nanovesicle platform using advanced polymer materials and machine learning, to direct nucleic acid therapeutics to the specific site of action with unparalleled precision. We are focused on delivery to the brain, CNS, lung, and other hard to reach areas of the body.
